Perrigo Ships Guaifenesin/PSE Tablets, But Single-Ingredient Snags Linger
This article was originally published in The Tan Sheet & The Rose Sheet
Executive Summary
Perrigo launches store brand Mucinex D, containing guaifenesin and PSE, manufactured by Allergan, but also suspends marketing its own guaifenesin product due to problems with an excipient used in the formula.
You may also be interested in...
Mutual Alleges Mucinex Monopoly In Extended-Release Guaifenesin
Mutual Pharmaceutical alleges in an antitrust suit that RB attempts to monopolize the extended-release guaifenesin OTC category with its Mucinex product. The suit says Mutual has lost “tens of millions” due to RB's failure to honor a contract to supply an “authorized generic” of the product.
Perrigo’s Mucinex Equivalent On The Cusp, But New Product Outlook Dims
The private labeler’s long-delayed guaifenesin launch now tentatively is set for March, CEO Joseph Papa says. But unclear timelines for other OTC launches caused Perrigo to lower its fiscal year consolidated new product sales outlook to $150 million from an initial projection of more than $190 million.
Perrigo Sets Generic Mucinex Launch After Patent Claim Decision
The private labeler clears a Reckitt Benckiser legal hurdle and will launch generic Mucinex (guaifenesin) by April. Watson has filed ANDAs for three Mucinex products and could be a good strategic partner for Perrigo, an analyst suggests.